It may, therefore, be concluded that resistance development towards everolimus is accompanied by elevated cdk2/cyclin A, driving tumor cells from the S- into the G2/M-phase, leading to a more aggressive tumor phenotype with enhanced growth capacity. Here, CDK2 is linked to neoplasm.